Essen BioTech

Ownership

Private

Employees

~500

Therapeutic Areas

OncologyImmunologyNeurology

Stage

Phase 1

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Modalities

CAR-T Cell TherapyMSC Stem Cell TherapyNK Cell Immune TherapyCytotoxic T Lymphocytes (CTLs) TherapyDendritic Cell Vaccines (DCv)Gene Therapy

Essen BioTech General Information

Developing immunotherapies with multiple Phase2 clinical programs including CAR-T therapies targeting hematologic cancers and glioma[3][4].

Contact Information

Website

https://essen-biotech.com/

Primary Industry

Biotech

Corporate Office

,
Bahrain

Drug Pipeline

CD19-BCMA CAR-T

Phase 1/2

Indications: Lorem ipsum dolor sit

Modality: Lorem ipsum

Drug Asset 2

Phase X

Indications: Lorem ipsum dolor sit

Modality: Lorem ipsum

Drug Asset 3

Phase X

Indications: Lorem ipsum dolor sit

Modality: Lorem ipsum

For full access to Essen BioTech's pipeline data

Key Partnerships

Collaborationswithrenowneduniversitiesandhospitalsworldwide"(specificinstitutionsnotnamed)[1]

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Essen BioTech Funding

No funding data available

Early Stage VC (Series A)	04-Jun-2020	$38M	Completed	Phase 1
Seed Round	12-Feb-2019	$8.5M	Completed	Startup

Interested in comprehensive profile data?

We'll help you find what you need

To view Essen BioTech's complete valuation and funding history, request access »

Essen BioTech Financial Metrics